10.22
price up icon3.76%   0.39
 
loading
전일 마감가:
$9.83
열려 있는:
$9.965
하루 거래량:
92,195
Relative Volume:
0.10
시가총액:
$485.83M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-1.943
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
+11.47%
1개월 성능:
+44.68%
6개월 성능:
+16.04%
1년 성능:
-38.70%
1일 변동 폭
Value
$9.94
$10.33
1주일 범위
Value
$8.90
$10.33
52주 변동 폭
Value
$5.035
$17.52

Regenxbio Inc Stock (RGNX) Company Profile

Name
명칭
Regenxbio Inc
Name
전화
240-552-8181
Name
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
직원
344
Name
트위터
@REGENXBIO
Name
다음 수익 날짜
2025-03-04
Name
최신 SEC 제출 서류
Name
RGNX's Discussions on Twitter

RGNX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
RGNX
Regenxbio Inc
10.21 485.83M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.38 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.48 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
652.82 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
260.13 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
258.31 26.40B 3.81B -644.79M -669.77M -6.24

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-11 다운그레이드 Goldman Buy → Neutral
2025-02-07 재개 Raymond James Outperform
2024-11-15 재개 Morgan Stanley Overweight
2024-10-10 재개 Raymond James Outperform
2024-06-07 개시 Goldman Buy
2024-03-11 개시 H.C. Wainwright Buy
2024-03-08 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2024-03-06 업그레이드 Leerink Partners Market Perform → Outperform
2024-02-21 재개 Raymond James Outperform
2023-11-01 개시 Stifel Buy
2023-06-02 개시 Robert W. Baird Outperform
2022-06-23 개시 Berenberg Buy
2021-12-15 개시 Wedbush Neutral
2021-10-19 재개 Morgan Stanley Overweight
2021-01-06 업그레이드 Raymond James Outperform → Strong Buy
2020-12-16 개시 UBS Buy
2020-06-25 재개 BofA/Merrill Buy
2020-05-13 개시 RBC Capital Mkts Sector Perform
2019-08-20 업그레이드 SVB Leerink Underperform → Mkt Perform
2019-06-18 재확인 Chardan Capital Markets Buy
2019-06-14 재개 Raymond James Outperform
2019-06-05 재확인 Chardan Capital Markets Buy
2019-02-25 업그레이드 Evercore ISI In-line → Outperform
2019-02-05 업그레이드 Raymond James Outperform → Strong Buy
2018-12-17 재확인 Chardan Capital Markets Buy
2018-11-08 재확인 BofA/Merrill Neutral
2018-08-08 재확인 Chardan Capital Markets Buy
2018-07-23 다운그레이드 BofA/Merrill Buy → Neutral
2018-07-10 재확인 Chardan Capital Markets Buy
2018-05-09 재확인 Barclays Overweight
2018-04-09 재확인 Chardan Capital Markets Buy
2018-03-12 다운그레이드 Evercore ISI Outperform → In-line
2018-02-13 개시 Mizuho Neutral
2017-11-09 재개 Morgan Stanley Overweight
모두보기

Regenxbio Inc 주식(RGNX)의 최신 뉴스

pulisher
09:02 AM

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights - Citizen Tribune

09:02 AM
pulisher
May 01, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Shares Fly 34% But Investors Aren't Buying For Growth - simplywall.st

May 01, 2025
pulisher
Apr 30, 2025

BlackRock, Inc. Reduces Stake in Regenxbio Inc: A Strategic Port - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

REGENXBIO to Host Conference Call on May 12 to Discuss First Qua - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

REGENXBIO Q1 2025 Earnings Call: Financial Results and Key Operations Update Coming May 12 - Stock Titan

Apr 30, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 27, 2025

Regenxbio Inc’s Market Journey: Closing Weak at 5.93, Down -5.72 - DWinneX

Apr 27, 2025
pulisher
Apr 24, 2025

Is REGENXBIO (NASDAQ:RGNX) A Risky Investment? - simplywall.st

Apr 24, 2025
pulisher
Apr 24, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Geode Capital Management LLC - Defense World

Apr 24, 2025
pulisher
Apr 22, 2025

Form 8-KCurrent report - ADVFN

Apr 22, 2025
pulisher
Apr 21, 2025

Regenxbio (RGNX) Gains Following Positive FDA Comments on Gene Therapies - GuruFocus

Apr 21, 2025
pulisher
Apr 17, 2025

Vanguard Group Inc. Trims Stake in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat

Apr 17, 2025
pulisher
Apr 08, 2025

RGNX stock touches 52-week low at $5.6 amid sharp annual decline - Investing.com Nigeria

Apr 08, 2025
pulisher
Apr 07, 2025

RGNX stock touches 52-week low at $5.6 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 02, 2025

When (RGNX) Moves Investors should Listen - news.stocktradersdaily.com

Apr 02, 2025
pulisher
Mar 31, 2025

Clear Street sets Regenxbio stock Buy rating, $50 target By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Clear Street sets Regenxbio stock Buy rating, $50 target - Investing.com India

Mar 31, 2025
pulisher
Mar 26, 2025

5 Reasons To Buy Regenxbio Right Now (NASDAQ:RGNX) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 21, 2025

REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing - insights.citeline.com

Mar 21, 2025
pulisher
Mar 21, 2025

RegenXBio Positioned Favorably Amid Competitor Safety Concerns, Justifying Buy Rating - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

REGENXBIO’s DMD Gene Therapy RGX-202 Generates Microdystrophin Expression in Additional Patients Treated in Phase 1/2 Trial - CGTLive™

Mar 20, 2025
pulisher
Mar 20, 2025

Regenxbio Rises After Duchenne Update And Sarepta Safety Scare - insights.citeline.com

Mar 20, 2025
pulisher
Mar 20, 2025

Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN

Mar 20, 2025
pulisher
Mar 20, 2025

Regenxbio’s RGX-202 continues to show promise in DMD - The Pharma Letter

Mar 20, 2025
pulisher
Mar 20, 2025

Regenxbio’s DMD gene therapy drives 122.3% biomarker uptick in three-year-old - Clinical Trials Arena

Mar 20, 2025
pulisher
Mar 20, 2025

Regenxbio stock target raised to $29 at Raymond James By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 19, 2025

REGENXBIO reports promising gene therapy trial results By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Baird maintains Regenxbio stock outperform rating, $39 target By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Baird maintains Regenxbio stock outperform rating, $39 target - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Regenxbio stock target raised to $29 at Raymond James - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial - Benzinga

Mar 19, 2025
pulisher
Mar 19, 2025

Regenxbio Says New Data Support Potential Gene Therapy for Duchenne Muscular Dystrophy - MarketScreener

Mar 19, 2025
pulisher
Mar 19, 2025

REGENXBIO reports promising gene therapy trial results - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

REGENXBIO: New Interim Data Reinforces Potential Of RGX-202Quick Facts - Nasdaq

Mar 19, 2025
pulisher
Mar 19, 2025

Breakthrough: REGENXBIO DMD Gene Therapy Achieves Unprecedented 122% Protein Expression - StockTitan

Mar 19, 2025
pulisher
Mar 18, 2025

Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Regenxbio at UBS Virtual CNS Day: Gene Therapy Advancements By Investing.com - Investing.com Canada

Mar 18, 2025
pulisher
Mar 17, 2025

H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy By Investing.com - Investing.com Philippines

Mar 17, 2025
pulisher
Mar 17, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The Corner - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

H.C. Wainwright cuts Regenxbio stock target to $34, maintains buy - Investing.com India

Mar 17, 2025

Regenxbio Inc (RGNX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$72.06
price down icon 0.47%
$21.45
price up icon 2.41%
$32.54
price up icon 0.43%
$27.18
price up icon 9.10%
$105.61
price up icon 3.06%
biotechnology ONC
$258.30
price up icon 1.38%
자본화:     |  볼륨(24시간):